Additional data needs to be submitted for the 2-dose course of its vaccine according to the committee, CNBC-TV-18 mentioned in a tweet.
#CNBCTV18Exclusive | Subject Expert Committee recommends EUA for ZyCoV-D; Cadila Health’s 3-dose COVID vaccine, sou… https://t.co/K7u6mSvDQ3
— CNBC-TV18 (@CNBCTV18Live) 1629445231000
The Ahmedabad-based drugmaker namely Cadila Healthcare Ltd applied for clearance of ZyCoV-D on July 1 basis the efficacy rate of 66.6% found in the late stage trial of more than 28,000 candidates across the nation.
Cadila Healthcare Ltd conducted the largest clinical trial spread over 50 centres.
Once approved, Zydus Cadila could be the second home-grown shot to get emergency usage clearance after Covaxin, in India. Also this was the first time adolescent population was a part of the clinical trial.